1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Bioextrax AB

Bioextrax AB

2.17
SEK
+0.05
(+2.36%)
-0.42EPS
116.47MMarket Cap
Nov 20Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
0.02
0.02
0.08
0.02
0.02
0.01
Basic EPS, GAAP
-0.01
- -
-0.06
-0.19
-0.42
-0.78
-1.09
-0.81
-0.52
-0.45
-0.43
Free Cash Flow per Basic Share
-0.01
- -
0.03
-0.36
-0.33
-0.7
-1.03
-0.87
-0.57
-0.66
-0.36
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
0.02
0.03
0.12
0.13
0.45
1.23
0.69
0.66
0.53
0.25
Tangible Book Value per Share
- -
0.02
0.03
0.12
0.13
0.45
1.23
0.69
0.66
0.53
0.25
Basic Weighted Avg Shares
15
15
15
10
13
14
17
27
33
40
43
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
2
1
1
1
Operating Margin (%)
- -
670
- -
- -
-25,573.09
-3,814.86
-4,725.82
-1,050.54
-3,405.63
-2,356.54
-3,427.71
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
Net Income, GAAP
- -
- -
-1
-2
-6
-11
-19
-22
-17
-18
-19
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
580
- -
- -
-25,586.15
-3,815.94
-4,725.82
-1,046.06
-3,366.6
-2,338.84
-3,407.52
Working Capital
- -
- -
- -
1
1
6
24
13
16
2
6
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
1
2
7
32
21
26
21
12
Return on Invested Capital (%)
- -
41.88
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
43.87
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
43.12
-365.02
-260.52
-386.17
-230.14
-95.08
-82.24
-74.42
-74.9
-124.01

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
40
48
48
Market Capitalization
112
133
116

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6
13
9
Cash, Cash Equivalents & STI
4
12
7
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
2
3
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
130.01%
-18.59%
Free Cash Flow
- -
51.33%
37.94%
Net Income, GAAP
- -
32.84%
2.12%
Sales/Revenue/Turnover
- -
320.62%
46.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.17
-0.15
-0.11
-0.11
-0.52
2025
-0.1
-0.11
-0.11
-0.13
-0.45
2026
-0.09
-0.1
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Carl Edvard Georg Hall
Full Time Employees
14
Sector
Health technology
Industry
Biotechnology
Address
Skiffervägen 76 Lund SN Sweden 224 78
IPO Date
Apr 28, 2020
Website
bioextrax.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Bioextrax AB (publ) is a Swedish biotechnology company focused on developing and commercializing advanced bio-based extraction solutions. The firm's proprietary platform technology facilitates the sustainable conversion of organic waste and raw materials into various eco-friendly products. Using a completely chemical-free and bio-based method, it recovers bioplastics (PHA) granules from diverse carbon sources, alongside producing organic hydrolyzed protein, keratin microfibres, bio-oils, and amino acids from materials such as poultry feathers. Established in 2014 and headquartered in Lund, Sweden, the company operates on a licensing model, providing its patented process technologies and expertise to material producers aiming for more cost-effective and environmentally sound manufacturing. Bioextrax continues to expand its collaborations, as evidenced by recent extended partnerships with chemical companies, underscoring its commitment to advancing green solutions and fostering a circular economy.